DWP817S004

DWP817S004 is an investigational drug candidate being developed by Daewoong Pharmaceutical for the treatment of sarcopenia, a condition defined by the age-related progressive loss of skeletal muscle mass, strength, and function. Currently in the preclinical stage, the compound is designed to mitigate muscle wasting and enhance muscle regenerative capacity. While the specific molecular target of DWP817S004 has not been publicly disclosed, it is part of Daewoong's strategic focus on metabolic and geriatric diseases, aiming to provide a pharmacological solution where few treatments currently exist to preserve physical mobility and quality of life in the elderly.